Skip to main content

Table 7 Multivariate Cox regression analyses of overall survival for four molecular subtypes of T1b breast cancer patients in the matched cohort

From: Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort

Variable

HoR + /HER2-

HoR + /HER2 + 

HoR-/HER2 + 

HoR-/HER2-

Multivariate Analysis

Multivariate Analysis

Multivariate Analysis

Multivariate Analysis

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

HR (95%CI)

P-value

GRADE

 I

reference

 

reference

 

reference

 

reference

 

 II

0.82(0.52–1.29)

0.39

0.74(0.30–1.85)

0.52

0.83(0.10–6.79)

0.87

1.29(0.31–5.44)

0.73

 III

0.93(0.58–1.48)

0.76

0.88(0.35–2.23)

0.79

0.87(0.11–6.77)

0.89

1.32(0.32–5.42)

0.70

SURGERY

 Breast-conserving

reference

 

reference

 

reference

 

reference

 

 Total mastectomy

1.14(0.61–2.11)

0.68

0.64(0.28–1.46)

0.29

0.28(0.09–0.84)

0.02

1.65(0.77–3.54)

0.20

 Modified radical mastectomy

1.64(0.81–3.30)

0.17

1.05(0.34–3.23)

0.94

0.40(0.09–1.70)

0.21

1.79(0.72–4.44)

0.21

RADIATION

 No

reference

 

reference

 

reference

 

reference

 

 Yes

0.63(0.35–1.14)

0.13

0.59(0.27–1.27)

0.18

0.33(0.10–1.06)

0.06

0.93(0.45–1.93)

0.84

CHEMOTHERAPY

 No

reference

 

reference

 

reference

 

reference

 

 Yes

0.94(0.66–1.34)

0.74

0.38(0.21–0.66)

 < 0.01

0.51(0.23–1.15)

0.01

0.44(0.28–0.67)

 < 0.0001

AGE (year)

 < 60

reference

 

reference

 

reference

 

reference

 

 ≥ 60

3.92(2.67–5.74)

 < 0.0001

4.93(2.37–10.28)

 < 0.0001

2.34(0.87–6.32)

0.09

3.34(1.81–6.15)

 < 0.0001

  1. Abbreviations: HoR hormone receptor, HER2 human epidermal growth factor receptor‐2, HR hazard ratio